Voyager Acquisition Clears Key Hurdle for Nasdaq Relaunch

Voyager Acquisition files mandatory executive clawback policy with the SEC, a final step before its Nasdaq listing as Veraxa Biotech AG. Shares rose 6% on the news.

Voyager Acquisition has addressed a significant regulatory requirement, filing a mandatory clawback policy to satisfy U.S. Securities and Exchange Commission (SEC) standards. This move is a crucial final step ahead of its planned Nasdaq listing under the new identity of Veraxa Biotech AG.

Share Price Responds to Regulatory Progress

Investors welcomed the compliance update, sending Voyager Acquisition shares higher by 6.02% to $12.33 in Friday's session. The stock now trades just below its 52-week peak of $12.90. However, with an annualized volatility reading of approximately 129%, the equity remains prone to substantial price swings.

The upcoming corporate merger will see the combined entity trade on the Nasdaq under the fresh ticker "VRXA." The associated warrants will continue to be listed under the symbol VACHW. These warrants become exercisable at $11.50 per share starting 30 days after the business combination is formally completed.

Closing a Reporting Gap for Executives

Over the past weekend, the company submitted an amended Form 10-K/A to finalize its 2025 annual report. The amendment's centerpiece is a new policy governing the recoupment of executive compensation. This clawback provision allows the company to recover incentive-based pay from its officers in the event of a material financial reporting error.

While this policy had been internally active since March 2025, it was not formally documented in the original SEC filing. Such regulatory precision is deemed essential for a seamless transition to the Swiss-based Veraxa Biotech AG and for securing permanent trading status under the new name.

Structural Flexibility Amidst Shareholder Redemptions

The path to this merger has been unconventional. Holders of more than 25 million Class A shares recently exercised their right of redemption, representing a staggering 99.67% of the class. Consequently, only about $885,000 remains in the company's trust account.

To maintain operational agility despite this capital outflow, the board of directors retains the authority to issue up to one million preferred shares without seeking further shareholder approval. This mechanism provides management with the flexibility to address future financing needs or to make strategic adjustments to the shareholder base.